Advancing beyond the twitch: The next-generation TetraGraph system
Jan 29, 2025
By Michael Noble, MBA - VP Global Marketing Senzime
The next-generation TetraGraph system revolutionizes neuromuscular monitoring by advancing beyond twitch-based technologies with electromyography (EMG) technology, ensuring precise and reliable monitoring even in challenging surgical environments like laparoscopic and robotic-assisted procedures.
By addressing residual paralysis and optimizing sugammadex dosing, the TetraGraph improves patient outcomes and enhances clinician confidence. Explore more about its impact and implementation resources to elevate your practice and transform patient safety.
I am thrilled about the ongoing roll-out of the next-generation TetraGraph system—an innovation that is making a significant impact in patient safety and care. First unveiled at ANESTHESIOLOGY® 2024 in Philadelphia, PA, this device is transforming how clinicians approach neuromuscular monitoring. Designed with usability and efficiency in mind, the next-generation TetraGraph system makes it easier than ever to monitor patients receiving neuromuscular blocks (NMBs) while also guiding precise dosing and reversal strategies.
Advancing beyond the twitch, the next-generation TetraGraph's electromyography (EMG) technology excels in monitoring patients during complex cases such as laparoscopic and robotic-assisted surgeries, where tucked arm positions often hinder acceleromyography (AMG) and peripheral nerve stimulators (PNS). This breakthrough ensures consistent and reliable monitoring even in challenging surgical environments.
Residual paralysis remains a significant challenge in the operating room, with studies consistently showing its adverse effects on patient safety and recovery.
Even when sugammadex is used, a quantitative train-of-four (TOF) monitor is critically needed, as studies have shown that 87% of patients receive too much sugammadex, while 13% require additional dosing. (1) Overdosing can lead to adverse side effects (2), further underscoring the importance of precise monitoring.
The next-generation TetraGraph system is purpose-built to combat these challenges by delivering unparalleled accuracy and reliability in TOF monitoring. Thanks to its proprietary TetraGraph Level-of-Block Gauge™ and Adaptive Intelligence™, this device simplifies the process of detecting and mitigating residual paralysis, enabling personalized dosing of neuromuscular blocking agents and reversal agents like sugammadex .
These advancements lead to better patient outcomes, reduced complications, and enhanced confidence for clinicians—ultimately transforming the standard of care in anesthesia.
If you’re as excited as I am about the potential of this groundbreaking technology, I encourage you to explore more about the next-generation TetraGraph at Senzime.com/NextGen.
Additionally, we’ve collaborated with anesthesia manager Erik Wroblewski to develop practical tips for implementing quantitative TOF monitoring in clinical practice—read his insights.
Finally, to experience the benefits of the TetraGraph firsthand, connect with your local representative for a complimentary demo. Find your nearest contact now.
Together, let’s redefine what’s possible in patient safety and perioperative care.
- Bowdle TA, Haththotuwegama KJ, Jelacic S, Nguyen ST, Togashi K, Michaelsen KE. A Dose-finding Study of Sugammadex for Reversal of Rocuronium in Cardiac Surgery Patients and Postoperative Monitoring for Recurrent Paralysis. Anesthesiology. 2023 Jul 1;139(1):6-15. doi: 10.1097/ALN.0000000000004578. PMID: 37027807.
- Liang W, Nguyen D, Anche G, et al. (January 19, 2025) Potential Adverse Effects of Sugammadex Administration: A Scoping Review. Cureus 17(1): e77666. DOI 10.7759/cureus.77666.
Michael Noble, MBA, VP Global Marketing at Senzime
Any questions on how Senzime can help to empower your practice? Feel free to contact me.
